Published: 2024-10-01
Perbandingan EVA, MVA dan FVA Perusahaan Sub Sektor Farmasi yang Terdaftar di BEI Pada Saat dan Sesudah Pandemi Covid 19
DOI: 10.35870/emt.v8i4.2216
Tutut Handayani, Iis Anisa Yulia, Dewi Fitrianti
Article Metrics
- Scopus Citations
- Google Scholar
- Crossref Citations
- Semantic Scholar
- DataCite Metrics
-
If the link doesn't work, copy the DOI or article title for manual search (API Maintenance).
Abstract
This research investigates the financial performance of pharmaceutical sub-sector companies listed on the Indonesia Stock Exchange (IDX) during and after the COVID-19 pandemic by analyzing Economic Value Added (EVA), Market Value Added (MVA), and Financial Value Added (FVA). The study aims to determine the impact of the pandemic on these companies' ability to create value for their shareholders and improve financial performance. A sample of 11 pharmaceutical companies was selected using purposive sampling, focusing on firms that have consistently reported financial data before, during, and after the pandemic. The Wilcoxon Signed Ranks Test was employed to assess the significance of differences in performance metrics over the two periods. Results show that there is no significant difference in the financial performance during and after the pandemic when measured using the EVA and FVA methods, indicating resilience in the intrinsic value creation capabilities of these companies. However, a notable difference was found in the MVA, reflecting changes in market perceptions and investor confidence. These findings suggest that while intrinsic financial metrics remained stable, external market factors significantly influenced company valuations.
Keywords
Financial Performance; COVID-19 Pandemic; Economic Value Added (EVA); Market Value Added (MVA); Financial Value Added (FVA)
Peer Review Process
This article has undergone a double-blind peer review process to ensure quality and impartiality.
Indexing Information
Discover where this journal is indexed at our indexing page.
Open Science Badges
This journal supports transparency in research and encourages authors to meet criteria for Open Science Badges.
How to Cite
Article Information
This article has been peer-reviewed and published in the Jurnal EMT KITA. The content is available under the terms of the Creative Commons Attribution 4.0 International License.
-
Issue: Vol. 8 No. 4 (2024)
-
Section: Articles
-
Published: 2024-10-01
-
License: CC BY 4.0
-
Copyright: © 2024 Authors
-
DOI: 10.35870/emt.v8i4.2216
AI Research Hub
This article is indexed and available through various AI-powered research tools and citation platforms. Our AI Research Hub ensures that scholarly work is discoverable, accessible, and easily integrated into the global research ecosystem.
Tutut Handayani, Universitas Nusa Bangsa
Program Studi Manajemen, Fakultas Ekonomi dan Bisnis, Universitas Nusa Bangsa, Kota Bogor, Provinsi Jawa Barat, Indonesia
Iis Anisa Yulia, Universitas Nusa Bangsa
Program Studi Manajemen, Fakultas Ekonomi dan Bisnis, Universitas Nusa Bangsa, Kota Bogor, Provinsi Jawa Barat, Indonesia
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Setkab.go.id. (2021, December 15). Menperin: Industri pengolahan kontributor terbesar pertumbuhan ekonomi triwulan II-2021. https://setkab.go.id/menperin-industri-pengolahan-kontributor-terbesar-pertumbuhan-ekonomi-triwulan-ii-2021/
-
Sunardi, N. (2018). Analisis Economic Value Added (EVA), Financial Value Added (FVA), dan Market Value Added (MVA) dengan time series approach sebagai alat penilaian kinerja keuangan (Studi pada industri konstruksi (BUMN) di Indonesia yang listing di BEI tahun 2013–2017). JURNAL SEKURITAS (Saham, Ekonomi, Keuangan dan Investasi), 2(1), 62–76.
-
Ulya, N. F., & Jatmiko, B. P. (2020, August 5). Pertumbuhan ekonomi RI minus 5,32 persen pada kuartal II-2020. Kompas. https://money.kompas.com/read/2020/08/05/120854826/pertumbuhan-ekonomi-ri-minus-532-persen-pada-kuartal-ii-2020

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Copyright Retention and Open Access License
Authors retain copyright of their work and grant the journal non-exclusive right of first publication under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
This license allows unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Rights Granted Under CC BY 4.0
Under this license, readers are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, including commercial use
- No additional restrictions — the licensor cannot revoke these freedoms as long as license terms are followed
3. Attribution Requirements
All uses must include:
- Proper citation of the original work
- Link to the Creative Commons license
- Indication if changes were made to the original work
- No suggestion that the licensor endorses the user or their use
4. Additional Distribution Rights
Authors may:
- Deposit the published version in institutional repositories
- Share through academic social networks
- Include in books, monographs, or other publications
- Post on personal or institutional websites
Requirement: All additional distributions must maintain the CC BY 4.0 license and proper attribution.
5. Self-Archiving and Pre-Print Sharing
Authors are encouraged to:
- Share pre-prints and post-prints online
- Deposit in subject-specific repositories (e.g., arXiv, bioRxiv)
- Engage in scholarly communication throughout the publication process
6. Open Access Commitment
This journal provides immediate open access to all content, supporting the global exchange of knowledge without financial, legal, or technical barriers.